Ethosuximidedrug info
ethosuximide 250 MG Oral Capsule
What it is used for
Zarontin is indicated for the control of absence (petit mal) epilepsy.
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective May 25, 2026. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
Description
Zarontin (ethosuximide) is an anticonvulsant succinimide, chemically designated as alpha-ethyl-alpha-methyl-succinimide, with the following structural formula: Each Zarontin capsule contains 250 mg ethosuximide, USP.
Also contains: polyethylene glycol 400, NF. The capsule contains D&C yellow No. 10; FD&C red No. 3; gelatin, NF; glycerin, USP; and sorbitol. Chemical Structure
Text above is quoted in full from the FDA-approved drug label published by openFDA, effective May 25, 2026. Matched to this product by RxNorm code. Cross-references to other sections of the full prescribing information have been removed, since they point to a document not shown here. Nothing else is changed: no sentence is shortened, reworded or summarised.
This page reproduces regulatory text for reference. It is not medical advice, and KenyRx is not a pharmacy or a prescriber. Talk to a doctor or pharmacist about whether a medicine is right for you.
See what it costs — price without insurance